Navigation Links
Thermo Fisher Scientific Executive Officers Adopting SEC Rule 10b5-1 Trading Programs
Date:8/20/2007

WALTHAM, Mass., Aug. 20 /PRNewswire-FirstCall/ -- Thermo Fisher Scientific Inc. (NYSE: TMO) announced today that certain executive officers, including Marijn E. Dekkers, president and chief executive officer, are adopting stock- trading programs under Securities and Exchange Commission (SEC) Rule 10b5-1 covering the future sale of company stock. Mr. Dekkers, who exercised options for and sold 300,000 shares over August 15-17, 2007, has adopted a plan for the future sale of up to an additional 780,000 shares, which he would acquire upon the exercise of stock options granted in 2002. Mr. Dekkers entered into this program in order to diversify his financial holdings, although he will continue to have a significant ownership interest in the company. After selling these shares, Mr. Dekkers would own shares, or share equivalents, and hold options totaling 1,860,378 shares.

These trading programs are based on SEC Rule 10b5-1, which protects company executives from possible claims of insider trading by permitting them to buy or sell a predetermined amount of their company's shares, as set forth in a planned acquisition or divestiture program that was adopted when the insider did not possess any material non-public information.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With an annual revenue rate of more than $9 billion, we employ 30,0
'/>"/>

SOURCE Thermo Fisher Scientific Inc.

Copyright©2007 PR Newswire.

Page: 1 2

Related biology technology :

1. Normalizing cDNA libraries using the EppendorfThermomixer
2. Rapid PCR* Using Active Tube Temperature Control On Thermos PCR Machines
3. A simple method to sequence from bacterial colonies using [a-33P] radiolabeled ddNTPs and Thermo Sequenase
4. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
5. UW-Madisons Beebe wins scientific award
6. Researchers say scientific reporting needs more perspective, less hype
7. Wisconsin stands at the center of scientific efforts to avert flu epidemics
8. Growth prompts new location for scientific instrument manufacturer
9. UW stem cell guru outlines scientific and political future
10. Wisconsin biotech sector featured in scientific magazine
11. Scientific Protein Laboratories Acquired by New York firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... , April 23, 2015 /CNW/ - A new and ... award from North America,s ... Comparison won Silver in the "Sustainability, service" category ... The Brandcheck "Competitor Comparison" is a service that ... American and Global peers. This benchmarking process shows ...
(Date:4/23/2015)... California (PRWEB) April 23, 2015 ... diagnostics refer to a series of genetic tests ... cystic fibrosis, Lou Gehrig's disease, Huntington's disease, and ... examining the gene composition and interaction in diseased ... disease as well as the response to treatment, ...
(Date:4/23/2015)... April 23, 2015 Proove ... Personalized Medicine, is excited to announce the launch ... . This profile assesses 62 genetic variations to ... information for commonly prescribed non-opioid pain medications, namely ... Neurontin), alprazolam (brand name Xanax) and acetaminophen (brand ...
(Date:4/23/2015)... Delpor, Inc. (Delpor), a biotechnology company focused ... Patent and Trademark Office has issued 2 new patents ... US Pat. No. 8,986,727 was issued on March 24, ... for the sustained release of therapeutic agents. The ... (zero-order) release of large and small molecules for several ...
Breaking Biology Technology:Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 2Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 3Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 2Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 3Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3
... , ANNAPOLIS, Md. , Feb. 1 ... biodefense company developing medical countermeasures against biological and chemical ... Paper in response to the Broad Agency Announcement (Solicitation ... Development Authority (BARDA) for the Advanced Research and ...
... , Feb. 1 Telik, Inc. (Nasdaq: TELK ) ... 12th Annual BIO CEO & Investor Conference in New York City ... time ( 12:00 p.m. Pacific time ).  A live and archived ... www.telik.com . , Telik, Inc. of Palo Alto, CA , is ...
... , SAN FRANCISCO , Feb. 1 ... a placement agent in GenVec, Inc.,s (Nasdaq: GNVC ) ... stock, and warrants to purchase 4.2 million shares of common stock, ... http://www.newscom.com/cgi-bin/prnh/20090911/MCFLOGO ) , "We have been working with the Merriman team ...
Cached Biology Technology:PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine 2PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine 3PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine 4Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 2Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 3Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 4Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 5Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 6Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 7
(Date:3/24/2015)... Fla. , March 24, 2015   ... management solutions, today announced that its U.are.U ® ... accessory retailer Goorin Bros . to achieve ... biometrics-based solution secures access to the POS terminal, ... increased risk of data breaches. ...
(Date:3/23/2015)... , March 23, 2015   HOYOS Labs ... management company, today announced that the Company will demonstrate ... both enterprise and consumers at Connect:ID on March 23 ... HOYOS Labs will highlight the IEEE Biometric Open ... ; and enterprise access control system. BOPS was ...
(Date:3/23/2015)... , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, announces its biometric payment ... campaign on CNBC television starting March 30 th . ... airing in New York markets. ... "We are excited about our new ad campaign following the ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... Cancer Research Center have, for the first time, induced ... achievement, the first demonstration of "hibernation on demand" in ... treat cancer and prevent injury and death from insufficient ... in essence, temporarily converting mice from warm-blooded to cold-blooded ...
... that are invisible by ordinary means of detection, according ... of Medicine in St. Louis. , The researchers demonstrated ... from the surrounding tissue by direct MRI scan--could be ... minutes after the mice were injected with the nanoparticles. ...
... the March issue of the journal Cancer Cell describes a ... to a new avenue for targeted cancer therapy. The compound, ... mouse model system and has low toxicity. The results of ... in phase I clinical trials. , Plk1 is a molecule ...
Cached Biology News:Buying Time Through Hibernation on Demand 2Buying Time Through Hibernation on Demand 3Buying Time Through Hibernation on Demand 4Buying Time Through Hibernation on Demand 5Nanoparticles offer new hope for detection and treatment 2Nanoparticles offer new hope for detection and treatment 3New drug shows promise as powerful anticancer agent 2